Abstract
The use of immune adjuvants such as toll-like receptor (TLR) agonists reflects a novel strategy in prostate cancer (PCa) therapy. However, interleukin......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
